US6322794B1 - Seroreactive epitopes on proteins of human papillomavirus (HPV) 18 - Google Patents

Seroreactive epitopes on proteins of human papillomavirus (HPV) 18 Download PDF

Info

Publication number
US6322794B1
US6322794B1 US08/164,768 US16476893A US6322794B1 US 6322794 B1 US6322794 B1 US 6322794B1 US 16476893 A US16476893 A US 16476893A US 6322794 B1 US6322794 B1 US 6322794B1
Authority
US
United States
Prior art keywords
seq
hpv18
seroreactive
proteins
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/164,768
Other languages
English (en)
Inventor
Conrad Bleul
Lutz Gissmann
Martin Müller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Priority to US08/164,768 priority Critical patent/US6322794B1/en
Priority to US08/466,285 priority patent/US5753233A/en
Assigned to BEHRING DIAGNOSTICS GMBH reassignment BEHRING DIAGNOSTICS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Assigned to BEHRING DIAGNOSTICS GMBH reassignment BEHRING DIAGNOSTICS GMBH SEE RECORDING ON REEL 8792, FRAME 0076. (RE-RECORD TO CORRECT THE NUMBER OF MICROFILM PAGES FROM 10 TO 15. Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Assigned to DADE BEHRING MARBURG GMBH reassignment DADE BEHRING MARBURG GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BEHRING DIAGNOSTICS GMBH
Application granted granted Critical
Publication of US6322794B1 publication Critical patent/US6322794B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the invention relates to seroreactive regions on proteins E1, E6 and E7 of human papillomavirus (HPV) 18.
  • the invention also relates to vaccines which contain peptides which embrace amino-acid sequences of the seroreactive regions of the said virus proteins and to diagnostic kits which contain the said peptides.
  • HPV18 is a specific type of human papillomavirus which was described for the first time in Proc. Natl. Acad. Sci., USA 80, 3813-3815 (1983).
  • HPV18 induces not only benign lesions of the anogenital tract but also malignant tumors of the neck of the uterus, of the penis and of the vagina. However, HPV18 is also found in genital scrapings from clinically symptom-free individuals. To date little is known about the immune response to infection by HPV18 and other papillomaviruses.
  • the object of the present invention is therefore to identify viral structures of HPV18 which are suitable as aids in the prophylaxis, the diagnosis and the therapy of HPV18-induced diseases in humans.
  • Knowledge about such structures (protein domains) is a prerequisite for the establishment of a test with which large quantities of human blood serum can be examined for the presence of specific HPVs.
  • the present invention embraces a seroreactive epitope on the El protein of HPV18 with the following amino-acid sequence
  • AACHKCIDFYSRIRELRHYSDSVYGDTLEKLT SEQ ID No:4
  • seroreactive epitopes on the E7 protein of HPV18 with one of the following amino-acid sequences
  • IDGVNHQHLPARR SEQ ID No:6
  • the invention also embraces peptides which contain either one or more than one amino-acid sequence(s) according to the invention of the abovementioned seroreactive epitopes.
  • the invention also embraces vaccines which are based on peptides which contain one or more amino-acid sequence(s) of the abovementioned seroreactive epitopes of the proteins of HPV18.
  • kits contains the peptides according to the invention.
  • this invention also embraces a diagnostic kit which contains polyclonal or monoclonal antibodies which are specifically directed against the seroreactive regions of HPV18.
  • Fuse 1 is derived from the bacteriophage fd and is described in Science 228, 1315-1317 (1985). The phages were plated out with Escherichia coli K91, replicas were made on nitrocellulose filters, and the filters were incubated with suitable polyclonal rabbit sera. Positive clones were isolated in several singling-out steps, and the immunoreactive peptide sequences were identified by DNA sequencing.
  • coli strain K802 (F ⁇ ga1K2 ga1T22 metB1 supE44 hsdr(2); Journal of Molecular Biology 16,118-133 (1966)) was used in the method of Hanahan in Journal of Molecular Biology 166, 557-580 (1988).
  • the tet-resistant colonies produce bacteriophages which are not infectious for the bacteria because of their F ⁇ phenotype.
  • the E. coli strain K91 F + , a derivative of E. coli K38, Virology 49, 45-60 (1972) was used.
  • Approximately 50 000 recombinant phages from the random bank described above were plated out with 0.2 ml of exponentially growing E. coli K91 cells in 3.5 ml of 0.5% agarose, which contained 10 mM MgSO 4 , on minimal agar plates. Replicas of the plates were made on nitro-cellulose filters and then incubated further at 37° C. on fresh minimal agar for 6 h in order to enhance the signal. The filters were then blocked with 10% low-fat milk in PBS for 60 min and incubated in 5% milk/PBS with a dilution of HPV-specific antisera of from 1:100 to 1:1000 overnight. It is also possible to use monoclonal antibodies in place of the specific HPV antisera.
  • the antisera were preadsorbed with sonicated K91 cells.
  • the filters were then washed 5 ⁇ , specifically in PBS/0.1% Tween 20 for 5 min and then at room temperature for 3 h with goat anti-rabbit antibodies or, in the case where monoclonal antibodies were used, incubated with anti-mouse peroxidase antibodies (1:1000) in 5% low-fat milk.
  • the filters were then washed in H 2 O for 30 min and then dried on filter paper.
  • Example 2 The same approach as in Example 2 was also chosen for HPV18 E6 protein. Since the polyclonal rabbit serum used cross-reacted with non-viral epitopes, besides the Western blot method, specific DNA fragments were used as probes in order to identify among all the reactive recombinants those with HPV18 E6 portions. From 70 000 recombinant phages, 15 were isolated and finally sequenced. The epitope HPV18 E6 No. 1 was thus found a total of 10 times in the investigated phage bank, for example.
  • USB United States Biochemicals
  • the polyethylene pins were incubated by the ELISA assay method with the above mentioned polyclonal rabbit sera, and bound antibodies were detected using protein A-peroxidase. A background produced by non-specific binding was quantified by protein A incubation without the first antibody.
  • the reactive peptides are located in regions which were identified by the phage screening as seroreactive epitope.
  • the pins were incubated with protein A-peroxidase 1:4000 at 37° C. for 1 h, followed by another washing step and staining with tetramethylbenzidine (TMB) for 15 min.
  • TMB tetramethylbenzidine
  • the staining step was stopped by withdrawing the pins from the staining solution and adding 100 ⁇ l of a 0.2 molar H 2 SO 4 solution. The absorption was then measured in an automatic ELISA reader.
  • the pins were incubated with ultrasound (water bath, 30 W, 48 KHz) at 60° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US08/164,768 1990-05-10 1993-12-10 Seroreactive epitopes on proteins of human papillomavirus (HPV) 18 Expired - Fee Related US6322794B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/164,768 US6322794B1 (en) 1990-05-10 1993-12-10 Seroreactive epitopes on proteins of human papillomavirus (HPV) 18
US08/466,285 US5753233A (en) 1990-05-10 1995-06-06 Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4015044 1990-05-10
DE4015044A DE4015044A1 (de) 1990-05-10 1990-05-10 Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
US69695391A 1991-05-08 1991-05-08
US94799292A 1992-09-21 1992-09-21
US08/164,768 US6322794B1 (en) 1990-05-10 1993-12-10 Seroreactive epitopes on proteins of human papillomavirus (HPV) 18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US94799292A Continuation 1990-05-10 1992-09-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/466,285 Division US5753233A (en) 1990-05-10 1995-06-06 Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18

Publications (1)

Publication Number Publication Date
US6322794B1 true US6322794B1 (en) 2001-11-27

Family

ID=6406140

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/164,768 Expired - Fee Related US6322794B1 (en) 1990-05-10 1993-12-10 Seroreactive epitopes on proteins of human papillomavirus (HPV) 18

Country Status (9)

Country Link
US (1) US6322794B1 (ja)
EP (1) EP0456197A1 (ja)
JP (3) JP3401022B2 (ja)
KR (1) KR100203547B1 (ja)
AU (1) AU650648B2 (ja)
CA (1) CA2042236C (ja)
DE (1) DE4015044A1 (ja)
IE (1) IE911584A1 (ja)
PT (1) PT97621B (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018487A1 (en) * 2001-02-16 2004-01-29 Lu Peter S. Methods of diagnosing cervical cancer
US20040229298A1 (en) * 2000-11-11 2004-11-18 Lu Peter S. Methods and compositions for treating cervical cancer
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US20050142541A1 (en) * 2003-12-23 2005-06-30 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
EP2026070A1 (en) 2002-09-09 2009-02-18 Arbor Vita Corporation Methods of diagnosing cervical cancer

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9503570D0 (en) * 1995-02-23 1995-04-12 Kodak Ltd Process and apparatus for the development of photographic materials
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
JP3618497B2 (ja) * 1996-12-27 2005-02-09 富士通株式会社 タンパク質の抗原決定基予測方法及びシステム
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DE60042556D1 (de) * 1999-09-16 2011-02-10 Eisai Inc Für polyepitop-polypeptide kodierende nukleinsäuren
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
SI1576967T1 (sl) * 2004-03-18 2008-02-29 Pasteur Institut Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
WO2016006873A1 (ko) * 2014-07-09 2016-01-14 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
CN105753980B (zh) * 2016-03-29 2019-04-02 上海市普陀区中心医院 一种hpv18 e6单克隆抗体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257754A2 (en) 1986-07-10 1988-03-02 The Board Of Trustees Of The Leland Stanford Junior University Synthetic peptides of human Papilloma virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257754A2 (en) 1986-07-10 1988-03-02 The Board Of Trustees Of The Leland Stanford Junior University Synthetic peptides of human Papilloma virus
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
Bleul, C. et al., Human papillomavirus Type 18 E6 and E7 Antibodies in Human Sera: Increased Anti-E7 Prevalence in Cervical Cancer Patients, Journal of Clinical Microbiology, vol. 29, 1579-1588 (1991).
Cole, S. T. et al., "Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of E6 and E7 gene products," Chem. Abstracts 107: 53075n (1987).
Durst, M. et al., "A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions," Proc. Natl. Acad. Sci. 80: 3812-3815 (1983).
Geysen, et al., 1984 "Use of peptide synthesis to probe viral antigens . . . " PNAS 81: 3998-4002.*
Geysen, H. M. et al., "Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein," Proc. Natl. Acad. Sci. 82: 178-182.
Geysen, H.M. et al., "Use of peptide synthesis to probe antigens for epitopes to a resolution of a single amino acid," Proc. Natl. Acad. Sci. 81: 3998-4002 (1984).
Hanahan, D., "Studies on Transformation of Escherichia coili with Plasmids," J. Mol. Biol. 166:557-580 (1983).
Lyons, L.B. et al., "The Genetic Map of the Filamentous Bacteriophage f1," Virology 49: 45-60 (1972).
Matlashenski, et al, 1986, "Expression of human papillomavirus . . . " J. Gen. Virol. 67: 1909-1916.*
Matlashewski, et al, 1986, "Expression of human . . . ". J. Gen. Virol. 67: 1909-1916.*
Matlashewski, G. et al., "The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies," Chem. Abstracts 106: 1115K (1987).
Parmley, S.F. et al., "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," Gene 73: 305-318 1988.
Sanger, F. et al., DNA sequencing with chain-terminating inhibitors, Proc. Natl. Acad. Sci. 74: 5463-5467 (1977).
Seedorf, et al, 1987, "Identification of early proteins of the . . . " EMBO J. 6(1): 139-144.*
Seedorf, et al, 1987, EMBO J. 6(1): 139-144.*
Seedorf, et al., 1987 "Identification of early proteins of the . . . " EMBO Journal 6(1): 139-144.*
Seedorf, K. et al., "Human papillomavirus Type 16 DNA Sequance," Virology 145: 181-185 (1985).
Selvey, et al, 1990, "Identification of B-epitopes . . . " J. Immunol. 145: 3105-3110.*
Selvey, et al, 1990, "Identification of B-epitopes . . . ". J. Immunol. 145:3105-3110.*
Smith, G. P., Filaments Fusion Phase: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface, Science 228:1315-1317.
Wood, W.B., "Host Specificity of DNA produced by Escheridia coli: Bacterial Mutations affecting the Restriction and Modification of DNA," J. Mol. Biol. 16:118-133 (1966).

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US20040229298A1 (en) * 2000-11-11 2004-11-18 Lu Peter S. Methods and compositions for treating cervical cancer
US8048676B2 (en) 2000-11-11 2011-11-01 Arbor Vita Corporation Systems of diagnosing cervical cancer
US20050255460A1 (en) * 2000-11-11 2005-11-17 Arbor Vita Corporation Methods of diagnosing cervical cancer
US20070099199A1 (en) * 2000-11-11 2007-05-03 Arbor Vita Corporation Methods and compositions for treating cervical cancer
US20070128699A1 (en) * 2000-11-11 2007-06-07 Lu Peter S Methods of diagnosing cervical cancer
US20040018487A1 (en) * 2001-02-16 2004-01-29 Lu Peter S. Methods of diagnosing cervical cancer
US7312041B2 (en) 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
US20080124702A1 (en) * 2001-02-16 2008-05-29 Lu Peter S Methods of diagnosing cervical cancer
US7972774B2 (en) 2001-02-16 2011-07-05 Arbor Vita Corporation Methods of diagnosing cervical cancer
EP2026070A1 (en) 2002-09-09 2009-02-18 Arbor Vita Corporation Methods of diagnosing cervical cancer
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US20090047660A1 (en) * 2003-12-23 2009-02-19 Peter Lu Antibodies for oncogenic strains of HPV and methods of their use
US20100209904A1 (en) * 2003-12-23 2010-08-19 Peter Lu Antibodies for oncogenic strains of HPV and methods of their use
US7399467B2 (en) 2003-12-23 2008-07-15 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US20050142541A1 (en) * 2003-12-23 2005-06-30 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US9611315B2 (en) 2003-12-23 2017-04-04 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use

Also Published As

Publication number Publication date
EP0456197A1 (de) 1991-11-13
JP3401022B2 (ja) 2003-04-28
JP3676195B2 (ja) 2005-07-27
AU7621291A (en) 1991-11-14
CA2042236C (en) 2002-07-09
PT97621B (pt) 1998-08-31
JP2001017190A (ja) 2001-01-23
KR910019641A (ko) 1991-12-19
PT97621A (pt) 1992-03-31
JP2001026600A (ja) 2001-01-30
IE911584A1 (en) 1991-11-20
KR100203547B1 (ko) 1999-06-15
AU650648B2 (en) 1994-06-30
JPH04227000A (ja) 1992-08-17
DE4015044A1 (de) 1991-11-14
JP3717755B2 (ja) 2005-11-16
CA2042236A1 (en) 1991-11-11

Similar Documents

Publication Publication Date Title
US6322794B1 (en) Seroreactive epitopes on proteins of human papillomavirus (HPV) 18
AU650868B2 (en) Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
JP3056502B2 (ja) ヒトパピローマウイルス１６型のｅ７タンパク質上の免疫原性領域
US7063963B2 (en) Determined DNA sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions
US6723317B2 (en) Antibodies specific for seroreactive regions on HPV 16 protein E1
JP2918904B2 (ja) ヒトパピローマウイルス潜伏性タンパク質に対する抗体、その診断システム及びその使用法
JP3859696B2 (ja) 乳頭腫ウイルスｈｐｖ３９のゲノムから誘導されるｄｎａ配列、ｉｎ ｖｉｔｒｏ診断及び免疫原組成物の生成への前記配列の応用
JP4612071B2 (ja) エプスタイン−バールウイルスペプチド及び該ペプチドに対する抗体
US5753233A (en) Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
JPH10113192A (ja) Ｈｃｍｖの糖タンパク質、およびｈｃｍｖワクチンおよびその産生法
Bleul et al. Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients
DK172647B1 (da) Samling af polypeptider og samling af antistoffer, som er karakteristiske for papillomavirus, og diagnostiske metoder, hvor
JPH0235086A (ja) 乳頭腫ウイルス（ｈｐｖ４９、ｈｐｖ５０、ｈｐｖ５４、ｈｐｖ５５）ゾンデ、この乳頭腫ウィルス（ｈｐｖ４９、ｈｐｖ５０、ｈｐｖ５４、ｈｐｖ５５）に遺伝的及び免疫学的に結びつけられた生成物、そして、乳頭腫ウィルス感染の試験管内診断とこれら乳頭腫ウィルスに対する生体内免疫化の方法
KR20090126256A (ko) 인간 거대세포바이러스(ｈｃｍｖ)의 재조합 항원
JP4563582B2 (ja) ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系
JP2002535965A (ja) ヒトパピローマウイルス・ウイルス様粒子を使用した中和アッセイ

Legal Events

Date Code Title Description
AS Assignment

Owner name: BEHRING DIAGNOSTICS GMBH, GERMANY

Free format text: ;ASSIGNOR:BEHRINGWERKE AKTIENGESELLSCHAFT;REEL/FRAME:008792/0076

Effective date: 19970731

Owner name: BEHRING DIAGNOSTICS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BEHRINGWERKE AKTIENGESELLSCHAFT;REEL/FRAME:008842/0428

Effective date: 19970731

AS Assignment

Owner name: DADE BEHRING MARBURG GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BEHRING DIAGNOSTICS GMBH;REEL/FRAME:009197/0667

Effective date: 19980217

Owner name: DADE BEHRING MARBURG GMBH,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BEHRING DIAGNOSTICS GMBH;REEL/FRAME:009197/0667

Effective date: 19980217

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20091127